
c-RET
Los inhibidores de c-RET se dirigen al protooncogén RET (Rearranged during Transfection), que codifica una tirosina quinasa receptora involucrada en el crecimiento, diferenciación y supervivencia celular. La activación anormal de la señalización de RET puede llevar a una proliferación celular descontrolada y resistencia a la apoptosis, contribuyendo al desarrollo de cánceres como el carcinoma medular de tiroides y el cáncer de pulmón de células no pequeñas. Inhibir c-RET puede inducir apoptosis en células cancerosas y es un enfoque prometedor en la terapia contra el cáncer dirigida. En CymitQuimica, ofrecemos una variedad de inhibidores de c-RET de alta calidad para apoyar su investigación en oncología, transducción de señales y apoptosis.
Se han encontrado 63 productos para "c-RET".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Treprostinil Sodium
CAS:Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).Fórmula:C23H33NaO5Pureza:99.67% - >99.99%Forma y color:SolidPeso molecular:412.5AD80
CAS:AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.Fórmula:C22H19F4N7OPureza:99.49% - 99.75%Forma y color:SolidPeso molecular:473.43Ref: TM-T4301
1mg44,00€1mL*10mM (DMSO)90,00€5mg96,00€10mg138,00€25mg268,00€50mg439,00€100mg645,00€500mg1.333,00€Pyrazoloadenine
CAS:Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.Fórmula:C5H5N5Pureza:99.02%Forma y color:SolidPeso molecular:135.1267SPP-86
CAS:SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Fórmula:C16H15N5Pureza:99.53%Forma y color:SolidPeso molecular:277.32Ref: TM-T16923
1mg46,00€5mg90,00€1mL*10mM (DMSO)90,00€10mg144,00€25mg281,00€50mg447,00€100mg650,00€500mg1.369,00€BBT594
CAS:BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.Fórmula:C28H30F3N7O3Pureza:99.57%Forma y color:White SolidPeso molecular:569.58WHI-P180 hydrochloride
CAS:WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.Fórmula:C16H16ClN3O3Forma y color:SolidPeso molecular:333.77RET V804M-IN-1
CAS:RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).Fórmula:C19H16N6OPureza:97.94% - 99.62%Forma y color:White SolidPeso molecular:344.37Ref: TM-T8467
1mg35,00€2mg50,00€5mg74,00€1mL*10mM (DMSO)82,00€10mg90,00€25mg157,00€50mg236,00€100mg334,00€200mg495,00€Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFórmula:C27H32FN9O2Pureza:97.88% - 99.89%Forma y color:White SolidPeso molecular:533.6Selpercatinib
CAS:"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."Fórmula:C29H31N7O3Pureza:99.87% - >99.99%Forma y color:White SolidPeso molecular:525.6RET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. It demonstrates inhibitory effects on BaF3 cells with the CCDC6-RETV804M mutation, with an IC50 of 0.715 μM. RET-IN-29 shows potential for research in non-small cell lung cancer (NSCLC).Fórmula:C22H22N6OForma y color:SolidPeso molecular:386.45RET-IN-16
CAS:RET-IN-16: Selective RET inhibitor, IC50s 3.98-15.05 nM for various RET mutations; anticancer properties.Fórmula:C31H29F3N8O2Forma y color:SolidPeso molecular:602.61TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Fórmula:C29H31F3N8OPureza:98%Forma y color:SolidPeso molecular:564.6RET-IN-8
CAS:RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Fórmula:C27H30N6O3Forma y color:SolidPeso molecular:486.57RET-IN-15
CAS:RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Fórmula:C27H28N8O2Forma y color:SolidPeso molecular:496.56RET-IN-22
CAS:RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-Fórmula:C29H31F3N6O4Forma y color:SolidPeso molecular:584.59XMD15-44
CAS:XMD15-44, a RET kinase inhibitor, demonstrates potent growth-inhibitory effects on RAT1 cells transformed by RET/C634R and RET/M918T, with IC50 values of 11.5 nM and 8.3 nM, respectively. It effectively inhibits RET kinase activity and signaling in human thyroid cancer cell lines harboring oncogenic RET alleles, thereby reducing cell proliferation.Fórmula:C29H29F3N4OForma y color:SolidPeso molecular:506.56RET-IN-6
CAS:RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).Fórmula:C30H29N7Forma y color:SolidPeso molecular:487.6RET-IN-12
CAS:RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).Fórmula:C30H30F3N5O4Forma y color:SolidPeso molecular:581.59DUN73423
CAS:DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.Fórmula:C19H16N6OPureza:98.03%Forma y color:SolidPeso molecular:344.37TG-89
CAS:TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFórmula:C26H34N6O3SPureza:98.68%Forma y color:White SolidPeso molecular:510.65
